morphine sulfate; naltrexone hydrochloride
EMBEDA (morphine sulfate; naltrexone hydrochloride) is ] . Approved for moderate to severe pain, around-the-clock opioid analgesic is needed for an extended period of time. First approved in 2009.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
EMBEDA is an extended-release oral capsule combining morphine sulfate (mu-opioid agonist) with naltrexone hydrochloride (mu-opioid antagonist) designed to provide around-the-clock analgesia while reducing opioid-induced constipation and abuse potential. It is indicated for moderate to severe pain requiring continuous opioid therapy for extended periods. The naltrexone component is released in the GI tract to block local opioid effects on smooth muscle, while morphine is absorbed systemically for analgesia.
Product is at peak commercial maturity with 15+ years post-launch; team focus likely shifting to maintaining market position against generic/biosimilar erosion and defensive indications.
] . Effects on the Gastrointestinal Tract and Other Smooth Muscle Gastric, biliary, and pancreatic secretions are decreased by morphine. Morphine causes a reduction in motility associated with an increase in tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is…
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain
Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
Conversion to Embeda With Rescue Trial
Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~4 years — strategic planning for patent cliff underway
EMBEDA offers stable, mature-stage career experience in a high-volume pain franchise with established commercial infrastructure and customer relationships; limited growth opportunity but strong platform for brand management fundamentals. Roles emphasize customer relationship management, payer negotiations, and defensive positioning as LOE approaches.